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Abstract: Objectives: To validate the gout activity score (GAS) against 
the gout impact scale in a primary care based gout cohort.  
Methods: This was a single-centre cross-sectional study. People with gout 
who participated in previous research at Academic Rheumatology, 
University of Nottingham, UK, and consented for participation in future 
studies were mailed a questionnaire in September 2015. Those returning 
completed questionnaires were invited to attend for a study visit at 
which blood was collected and musculoskeletal examination was performed. 
The Gout Assessment Questionnaire, which contains the gout impact scale 
(GIS), and short form (SF) 36v2 questionnaires were completed. The GAS3-
step-c score was calculated. Spearman's correlation coefficient was 
calculated to examine correlation between GAS and SF-36 v2, and GIS. 
Statistical analyses were performed using PASW v22.  
Results: 102 (93% men) of the 150 participants who were mailed a 
questionnaire attended the study visit. Their mean (SD) age, BMI, serum 
uric acid and GAS were 67.94 (9.93) years, 29.96 (4.57) kg/m2, 5.25 
(1.75) mg/dl, and 2.99 (0.74) respectively. There was moderate 
correlation between GAS and gout concern overall, unmet gout treatment 
need, and gout concern during an attack components of GIS (r= 0.306 to 
0.453), but no to poor correlation between GAS and summary scores and 
scales of SF-36 v2 (r= -0.090 to -0.251).  
Conclusion: This first study to validate GAS against the GIS found 
moderate correlation. However, this study did not examine the predictive 
validity of GAS, and prospective studies are needed before GAS can be 
used widely. 
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Abstract 
Objectives To validate the gout activity score (GAS) against the gout impact scale in 
a primary care based gout cohort.  
Methods This was a single-centre cross-sectional study. People with gout who 
participated in previous research at Academic Rheumatology, University of 
Nottingham, UK, and consented for participation in future studies were mailed a 
questionnaire in September 2015. Those returning completed questionnaires were 
invited to attend for a study visit at which blood was collected and musculoskeletal 
examination was performed. The Gout Assessment Questionnaire, which contains 
the gout impact scale (GIS), and short form (SF) 36v2 questionnaires were 
completed. The GAS3-step-c score was calculated. Spearman’s correlation coefficient 
was calculated to examine correlation between GAS and SF-36 v2, and GIS. 
Statistical analyses were performed using PASW v22.  
Results 102 (93% men) of the 150 participants who were mailed a questionnaire 
attended the study visit. Their mean (SD) age, BMI, serum uric acid and GAS were 
67.94 (9.93) years, 29.96 (4.57) kg/m2, 5.25 (1.75) mg/dl, and 2.99 (0.74) 
respectively. There was moderate correlation between GAS and gout concern 
overall, unmet gout treatment need, and gout concern during an attack components 
of GIS (r= 0.306 to 0.453), but no to poor correlation between GAS and summary 
scores and scales of SF-36 v2 (r= -0.090 to -0.251).  
Conclusion This first study to validate GAS against the GIS found moderate 
correlation. However, this study did not examine the predictive validity of GAS, and 
prospective studies are needed before GAS can be used widely.  
Keywords: Gout, disease activity, quality of life 
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Introduction. Gout is the commonest inflammatory arthritis and affects between 1.4 
to 2.5% of the general population (1). It is the only chronic arthritis that can be 
“cured” by appropriate long-term urate lowering treatment (ULT) (2). Scire and 
colleagues recently developed the first composite disease activity score (DAS) for 
gout, the gout activity score (GAS) by employing a Delphi exercise and using a data 
driven approach (3). Data from a cohort of Italian gout patients recruited from 
secondary care rheumatology clinics were used for this purpose, and external 
validation was carried out in a subset of the cohort (3). GAS is simple to use and 
correlated moderately with the Health Assessment Questionnaire (HAQ) and Short 
Form-36 (SF-36) physical component score in this cohort (3). However, as GAS was 
developed in a secondary care gout population which may have an over-
representation of people with difficult to treat and/or severe gout, it is important to 
examine its relationship with gout specific quality of life (QOL) measures in a primary 
care gout population. Moreover, the relationship between GAS and gout specific 
QOL measures, such as the Gout Impact Scale (GIS) (4) and its individual domains 
(e.g. gout concern overall, gout medication side effects etc.) have not been 
examined before.  
The purpose of this study was to validate GAS in people with gout recruited from 
primary care. The specific objectives were to examine the correlation between GAS 
and sub-scales of GIS and summary scores and individual scales of SF-36v2. As 
GIS is a gout specific QOL instrument, we hypothesized that it will have a stronger 
correlation with GAS than SF-36v2 which may be influenced by comorbidities. 
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Methods Study design and recruitment. This was a single-centre cross-sectional 
study. People with gout who participated in gout research at Academic 
Rheumatology, University of Nottingham, and gave consent to receive information on 
future studies were mailed a postal questionnaire in September 2015. These 
participants had participated in a case-control study aimed at developing a biomarker 
for gout and osteoarthritis (recruited in 2008) (5), and in an observational study of the 
effect of physician initiated nurse led treatment of gout on long-term ULT persistence 
(recruited in 2010-2011) (6). All participants in the case-control study met the 
preliminary American Rheumatism Association criteria for gout (7), while all 
participants in the latter study had crystal proven gout (5, 6). Their disease and 
demographic characteristics have been published previously (5, 6). The current 
study was approved by the University of Nottingham Medical School Ethics 
Committee. 
The postal questionnaire enquired about demographic characteristics, comorbidities, 
medication use, healthcare use for gout and number of gout attacks in the last year, 
and included the SF-36v2 and Gout Assessment Questionnaire (GAQ) 2.0. Those 
who returned completed questionnaires were invited to attend for a study visit at 
which blood was collected for serum uric acid (SUA) and creatinine measurement. 
Participants’ height (metres), weight (kilograms) and blood pressure (mm Hg), were 
measured, and musculoskeletal examination including tophus count was performed.  
Calculation of GAS and QOL scores Scire et al developed two simple to use 4-
variable GAS scores, the GAS3-step-c and the GAS1-step-c with slightly different 
components (4). Of these, the GAS3-step-c had the best metric and was externally 
validated in a sub-set of the KING cohort (4). We calculated GAS3-step-c using data on 
self-reported number of gout attacks in the previous 12 months, SUA, patient 
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reported visual analogue score (VAS) about gout and number of tophi (GAS3-step-c = 
(0.09 * last 12 month attacks) + [1.01 * square root (serum uric acid)] + [0.34 * VAS 
patient] + [0.53 * ln (1+ tophi number)]) (4) [Appendix A, document S1; See the 
supplementary material associated with this article online]. The VAS patient was derived 
from the following question of GAQ 2.0 “Considering all the ways gout affects you, 
circle a number on the scale for how well you have been doing for the past 4 
weeks”(8). 
SF-36v2 a global health related QOL measure and GIS were calculated as described 
earlier (4, 9). SF-36v2 has eight scales and two summary scores. All scales and 
summary scores are scored separately, with higher values indicating better QOL. 
GIS evaluates the current impact of gout in five areas, specifically: gout concern 
overall; gout medication side effects; unmet gout treatment needs; well-being during 
an attack; and gout concern during an attack. All subscales of GIS are scored 
separately on a 0 to 100 score [Appendix A, document S2), with higher scores 
indicating a greater impact (4). Remission GAS score for gout was defined as no 
gout attacks in the last 12 months, no tophi, serum uric acid <6 mg/dl, and both 
patient global assessment for gout activity and gout pain ≤2 on a 1-10 scale (10).  
Statistical analysis Number (%), mean (standard deviation (SD)), median 
(interquartile range (IQR)) were used for descriptive purposes. Spearman’s 
correlation coefficient was calculated to examine the correlation between GAS, SF-
36v2 and GIS as the data were not normally distributed. All statistical analysis were 
performed using PASW v22. p<0.05 (two tailed) was regarded as statistically 
significant.  
Funding source: This study was supported by Nottingham University Hospitals 
NHS Trust Charity.  
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Results 102 of the 150 gout patients who were sent postal questionnaires attended 
for the study visit. Their mean (SD) age, age of onset of gout, BMI, and SUA level 
were 67.94 (9.93) years, 50.13 (13.52) years, 29.96 (4.57) kg/m2, and 5.25 (1.75) 
mg/dl. 95 (93.14%) were men, 88 (86.3%) were on ULT, and 2 (1.96%) had tophi. 
Their mean (SD), and median (IQR) GAS was 2.99 (0.74), and 2.71 (2.48 – 3.38) 
respectively.  
There was moderate correlation between GAS and gout concern overall, unmet gout 
treatment need, and gout concern during an attack, and weak correlation with gout 
medication side effects subscales of GIS with r = 0.383, 0.453, 0.306, 0.227 
respectively (Table S1). However, there was no correlation between GAS and 
wellbeing during gout attack subscale of GIS.  
There was very weak to weak correlation between the mental component summary 
scale, and bodily pain, general health, mental health, social functioning domains of 
SF-36 v2 and GAS (r= -0.196 to -0.251), (Table S2).  
Forty-four participants met the preliminary remission criteria for gout (10). Their 
mean (SD) GAS was 2.5 (0.2), and ranged from 1.81 to 2.78. On the contrary, the 
mean (SD) GAS score for participants not in remission was 3.13 (0.55), and ranged 
between 2.83 and 3.55. 
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Discussion Until recently there was no composite measure of disease severity in 
gout. Consequently, the concept of overall gout severity has remained ambiguous 
and difficult to measure. Scire et al developed the first global measure of gout activity 
in 2016 and externally validated it in a hospital cohort (3). This is the first study to 
attempt to validate GAS in people with gout recruited from primary care by 
examining its correlation with GIS. This study found that GAS has a significantly 
stronger correlation with some components of gout specific QOL measures e.g. gout 
concern overall, unmet gout treatment need than with a generic overall QOL 
measure such as SF-36. GAS has the potential of being used as a marker of disease 
severity, before beginning treatment, and of assessing improvements in gout in a 
composite way over time. It is easy to measure, can be calculated using web-based 
calculators just as the disease activity score (DAS) in RA, and provides a measure 
that will be easy for the patients and their treating doctors to understand. It serves as 
an important improvement over GIS, which is cumbersome, requires answers on a 
Likert scale to multiple questions, and cannot be used readily in clinical practice.  
This was a well-treated cohort of people with gout and the mean GAS score was low. 
However, even in this population, there was moderate correlation between GAS and 
gout concern overall, gout concern during attack and unmet treatment need sub-
scales of GIS. As expected, GAS, a measure of intercritical gout disease activity did 
not correlate with wellbeing during gout attack sub-scale of GIS, and further research 
is required to develop measures that can measure severity of acute gout. Thus, the 
findings of this study provide construct and external validity to GAS, even in a 
population with well treated gout. Apart from this, a GAS score of 2.8 was able to 
differentiate people in remission.  
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Despite being endorsed by OMERACT for use in gout studies, there was a weaker 
correlation between GAS and SF36 v2 than between GAS and GIS. Moreover, the 
physical component score and mental component score of SF36 v2 in this study 
population correlated less well with GAS than in the study by Scire et al (3). This 
may be due to the fact that participants in our study were recruited from the 
community, and had a significantly lower burden of tophaceous gout and other 
comorbidities than those participants in the KING study.  
Strengths of this study include primary care based recruitment, and systematic 
assessment for tophus by a single trained research nurse with >10 years’ experience 
of assessing people with gout. We also note some study limitations: this was a 
cross-sectional study, and we did not directly examine the value of GAS in predicting 
the occurrence of flare or change ULT dose. Additionally, even though there is a lack 
of consensus concerning the timeframe over which absence of disease activity 
defines remission, this study used a single time point, which is not ideal. Also the 
proportion of gout patients on urate lowering treatment in this study is significantly 
higher than the proportion on urate lowering treatment in community based studies 
which may limit the generalisability of our findings.  
In summary, this study provides external validity to support the use of an instrument 
to define disease activity in gout. GAS showed validity in assessing disease-specific 
health in patients with gout. However, given the study limitations, further prospective 
studies carried out in less well treated primary care gout cohorts are needed before 
GAS can be adopted for use.  
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Appendix A. Supplementary data 
Supplementary data (Documents S1-S2) associated with this article can be found in the online 
version at … 
 
Highlights:  
 Gout activity score reflects severity of intercritical gout and not of wellbeing 
during acute gout. 
 Gout activity score is only weakly influenced by some measures of overall 
QOL.  
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Table S1 Correlation between Gout Activity Score and individual domains of Gout Impact 
Scale 
 Spearman’s correlation coefficient p value 
Gout concern overall  0.383 <0.001 
Gout Medication side effect 0.227 0.022 
Unmet gout treatment need 0.453 <0.001 
Wellbeing during attack  0.077 0.441 
Gout concern during attack 0.306 0.002 
 
 
 
Table S2 Correlation between Gout Activity Score and summary scales and domains of 
Short Form-36 v2 
 Spearman’s correlation coefficient p value 
Physical component summary scale -0.148 0.136 
Mental component summary scale -0.196 0.049 
Physical functioning -0.090 0.367 
Role physical -0.162 0.162 
Bodily pain -0.235 0.018 
General health -0.204 0.040 
Vitality -0.171 0.085 
Role Emotional -0.190 0.056 
Mental health -0.225 0.023 
Social functioning -0.251 0.011 
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Calculating the Gout Impact Scale (GIS) subscales 
 
GIS subscales were calculated by transforming the 1-5 responses on a 100-0 scale 
(1=100, 2=75, 3=50, 4=25, 5=0) for questions 1 a-h and j-l; 2 a-d; and 1-5 responses on a 
0-100 scale (1=0, 2=25, 3=50, 4=75, 5=100) for questions 1 i,m, and 3 a-g; and 
calculating the mean of questions: 
Q1 a-d for gout concern overall  
Q1 e, k for gout medication side effects  
Q1 i, l, m for unmet gout treatment need  
Q2 a-d, and 3 a-g for well-being during attack  
Q1 f-h, and j for gout concern during attack. 
The subscales were calculated if at least half of the items were completed.  
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